Postoperative length of stay comparison associated with a switch from alvimopan to naloxegol in patients undergoing major small and large bowel procedures

Clicks: 14
ID: 332396
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #218 of 247 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 247 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
PURPOSE: This retrospective analysis compares postoperative length of stay in patients undergoing colorectal surgery who received naloxegol or alvimopan as part of an Enhanced Recovery After Surgery (ERAS) protocol. METHODS: This is a systemwide retrospective cohort. The community health system switched from alvimopan to naloxegol as the peripherally acting mu-opioid receptor antagonist (PAMORA) agent used in the colorectal ERAS protocol in December 2024. Adult patients who underwent colorectal surgery and received one PAMORA dose for surgical discharge dates between May 2024 and August 2025 were included. RESULTS: There was no difference in median length of stay (alvimopan 3.2 days [2.2-6.2] versus naloxegol 3.3 days [2.2-5.9], p = 0.881). Median bowel function return was achieved sooner in patients receiving alvimopan (1.4 days [1.1-2.1] versus 1.7 [1.2-2.4], p = 0.015), however all-cause 30-day readmission rates were higher in the alvimopan group (15.2% versus 8.2%, p = 0.021). Patients in the alvimopan group were more likely to receive a dose prior to the procedure than naloxegol (89.1% versus 76.4%, p < 0.001). A subgroup analysis of those patients revealed there was no difference in median length of stay, median bowel function return, or incidence of postoperative ileus, with higher readmission rates in the alvimopan group (p = 0.005). The average PAMORA cost per admission who received alvimopan was approximately 16 times more expensive than naloxegol. CONCLUSION: Switching from alvimopan to naloxegol in colorectal ERAS protocols is a potential cost-saving initiative for formulary management that was associated with similar observed length of stay and postoperative ileus rates.
Reference Key
openalex_W7221781089 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hanna M. Schultz, Doug Raiff
Are you one of these authors? Claim your profile
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag344
URL
https://doi.org/10.1093/ajhp/zxag344
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.